Francesca CONRADIE to Rifampin
This is a "connection" page, showing publications Francesca CONRADIE has written about Rifampin.
Connection Strength
1,291
-
Risk factors for and timing of presumptive recurrent TB. Int J Tuberc Lung Dis. 2024 Nov 01; 28(11):527-533.
Score: 0,211
-
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial. Lancet Respir Med. 2024 Dec; 12(12):975-987.
Score: 0,210
-
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022 09 01; 387(9):810-823.
Score: 0,182
-
A call to action: Addressing the reproductive health needs of women with drug-resistant tuberculosis. S Afr Med J. 2016 Mar 17; 106(4):30-1.
Score: 0,116
-
Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther. 2011; 16(4):527-34.
Score: 0,081
-
Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024 Aug 01; 102(8):600-607.
Score: 0,051
-
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024 Sep; 24(9):1003-1014.
Score: 0,051
-
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet. 2022 11 26; 400(10366):1858-1868.
Score: 0,046
-
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect Dis. 2022 04; 22(4):496-506.
Score: 0,043
-
Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study. Lancet Infect Dis. 2022 02; 22(2):242-249.
Score: 0,043
-
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis. 2021 07; 21(7):975-983.
Score: 0,041
-
Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur Respir J. 2020 03; 55(3).
Score: 0,038
-
Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease. Clin Infect Dis. 2020 01 16; 70(3):425-435.
Score: 0,038
-
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med. 2019 12; 7(12):1048-1058.
Score: 0,037
-
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2019 03 28; 380(13):1201-1213.
Score: 0,036
-
Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. Appl Health Econ Health Policy. 2018 Feb; 16(1):43-54.
Score: 0,033
-
Persistently high early mortality despite rapid diagnostics for drug-resistant tuberculosis cases in South Africa. Int J Tuberc Lung Dis. 2017 10 01; 21(10):1106-1111.
Score: 0,032